CalciMedica, Inc.
About CalciMedica, Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$29.6M
- Total assets
- $13.6M
- Market cap
- $16.7M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $23.1M
- Operating income
- -$23.1M
- Income tax
- $0
- Net income
- -$29.6M
- EPS (basic)
- $-1.97
- EPS (diluted)
- $-1.97
Balance sheet
- Total assets
- $13.6M
- Current assets
- $13.5M
- Total liabilities
- $20.2M
- Current liabilities
- $3.8M
- Shareholders’ equity
- -$6.6M
Cash flow
- Operating cash flow
- -$21.2M
- Investing cash flow
- $9.6M
- Financing cash flow
- $15.2M
- Net cash flow
- $3.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $16.7M
- EPS (diluted)
- $-1.97
- Shares outstanding
- 17.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 25, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $29.6M.
- Trading 86% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review CalciMedica, Inc..
Write a review
News about CalciMedica, Inc.
News & sentiment via Polygon.io
